Please try another search
Ascendis Pharma A/S reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was EUR 95.89 million compared to EUR 33.59 million a year ago. Net loss was EUR 131.04 million compared to EUR 110.91 million a year ago. Basic loss per share from continuing operations was EUR 2.3 compared to EUR 1.98 a year ago. Diluted loss per share from continuing operations was EUR 2.3 compared to EUR 1.98 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 137.7 | 48.03 | 47.39 | 33.59 |
Gross Profit | 118.24 | 40.65 | 34.46 | 28.97 |
Operating Income | -36.61 | -134.41 | -140.84 | -143.68 |
Net Income | -86.88 | -162.22 | -121.43 | -110.91 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 825.59 | 873.21 | 823.82 | 966.27 |
Total Liabilities | 971.28 | 946.65 | 758.98 | 799.07 |
Total Equity | -145.7 | -73.43 | 64.84 | 167.2 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -42.47 | -124.72 | -153.13 | -147.04 |
Cash From Investing Activities | 6.65 | 22.22 | 46.96 | 210.65 |
Cash From Financing Activities | -6.06 | 143.36 | -2.31 | -0.702 |
Net Change in Cash | -49.1 | 47.05 | -107.06 | 56.51 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review